Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (Rituximab) [3]

British Journal of Haematology

Volumn 114, Issue 1, 2001, Pages 244-245

  Ahrens, Norbert ^a   Kingreen, Dorothea ^a   Seltsam, Axel ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AIHA; Anti CD20; Refractory autoimmune haemolytic anaemia; Rituximab

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

AGED; ANTIGEN RECOGNITION; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CASE REPORT; CHILL; ERYTHROCYTE; HEMOLYSIS; HUMAN; LETTER; MALE; PRIORITY JOURNAL; REFRACTORY ANEMIA;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; MALE;

EID: 0034940321     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02873-6.x     Document Type: Letter

References (5)

1. Rituxan in the treatment of cold agglutinin disease
2. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab
3. Rituximab
4. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease
5. Auto-immune hemolytic anemias